Organic cation transporter 1 (OCT1) is one of the membrane proteins in the large solute carrier (SLC) family. It participates in the transport of organic cations, i.e. nutrients, neurotransmitters, metabolites or drugs in an electrogenic manner and translocate various cationic cytostatics. Knowledge concerning the expression of drug transporters in tumor cells may help to develop cytotoxic agents that are targeted to specific tumors. OCT1 expression and its relationship to the proliferation of cancer cells, development of metastases and resistance to chemotherapy has been observed in solid tumors. There is no data concerning the significance of OCT1 expression in the clinical course and treatment results in acute myeloid leukemia (AML). The objective of the study was firstly to evaluate OCT1 mRNA expression in patients with newly diagnosed de novo AML, and secondly to compare the obtained results to the healthy control group as well as analyze them according to leukemia subtypes, CD34 expression, cytogenetic and molecular factors and treatment results. 101 patients with AML, excluding the subtype classified as M3 by French-American-British (FAB) criteria, were analyzed. The control group consisted of 26 healthy individuals. The evaluated material was bone marrow (BM). Real-time quantitative polymerase chain reaction (RQ-PCR) was used in the study as a method of evaluating OCT1 mRNA expression. The study showed a statistically significant lower expression of OCT1 mRNA in patients with AML in comparison to the control group. The level of OCT1 mRNA expression was lowest for CD34+ leukemia. No significant correlation between OCT1 mRNA expression and cytogenetic and molecular factors was observed. A significant influence of OCT1 mRNA expression on the clinical outcome of the disease was observed: patients with lower expression had higher chances of achieving complete remission (CR) and longer overall survival (OS).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12253-016-0161-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IL-17A activates JAK/STAT signaling to affect drug metabolizing enzymes and transporters in HepaRG cells.
Mol Immunol
November 2024
Department of Pharmacy, People's Hospital of Peking University, Beijing, China. Electronic address:
Article Synopsis
- IL-17A is a pro-inflammatory cytokine linked to autoimmune disorders and affects liver drug metabolism, though its exact impact on drug-metabolizing enzymes and transporters is not well understood.
- This study investigates how IL-17A influences DMETs (drug-metabolizing enzymes and transporters) in liver cells (HepaRG) through specific molecular techniques, revealing it inhibits the expression of multiple key enzymes and transporters.
- The findings suggest that altered DMET regulation due to IL-17A in immune-related conditions, like psoriasis, may lead to changes in how drugs are processed in the body, potentially causing unexpected drug interactions in patients.
Genetic polymorphism in untranslated regions of PRKCZ influences mRNA structure, stability and binding sites.
BMC Cancer
September 2024
Department of Community Health Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
Article Synopsis
- Variations in untranslated regions (UTR) of the PRKCZ gene impact regulatory pathways, which can affect diseases related to the heart, nervous system, and cancer.
- The study analyzed data on PRKCZ variants to assess their effects on transcription factor and microRNA binding sites, utilizing various bioinformatics tools to examine RNA structure and gene expression.
- Results showed that multiple UTR variants, especially in the 5' and 3' regions, significantly impacted binding sites and RNA structure, indicating that PRKCZ is a gene with limited tolerance for genetic variation.
Lack of effects of polystyrene micro- and nanoplastics on activity and expression of human drug transporters.
Environ Toxicol Pharmacol
October 2024
Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, Rennes 35000, France. Electronic address:
Micro- and nanoplastics (MPs/NPs) constitute emerging and widely-distributed environmental contaminants to which humans are highly exposed. They possibly represent a threat for human health. In order to identify cellular/molecular targets for these plastic particles, we have analysed the effects of exposure to manufactured polystyrene (PS) MPs and NPs on in vitro activity and expression of human membrane drug transporters, known to interact with chemical pollutants.
View Article and Find Full Text PDFOntogeny of Hepatic Organic Cation Transporter-1 in Rat and Human.
Drug Metab Dispos
October 2024
Drug Delivery and Disposition (S.F., Pa.A., Pi.A.), Laboratory of Cell Metabolism (A.B.S., M.B.), Clinical Pharmacology and Pharmacotherapy (K.A.), Department of Pharmaceutical and Pharmacological Sciences, and Department of Development and Regeneration (K.A.), KU Leuven, Leuven, Belgium; and Department of Hospital Pharmacy, Erasmus University Medical Centre, Rotterdam, The Netherlands (K.A.)
The organic cation transporter (OCT)-1 mediates hepatic uptake of cationic endogenous compounds and xenobiotics. To date, limited information exists on how Oct1/OCT1 functionally develops with age in rat and human livers and how this would affect the pharmacokinetics of OCT substrates in children or juvenile animals. The functional ontogeny of rOct/hOCT was profiled in suspended rat (2-57 days old) and human hepatocytes (pediatric liver tissue donors: age 2-12 months) by determining uptake clearance of 4-[4-(dimethylamino)styryl]-N-methylpyridinium iodide (ASP+) as a known rOct/hOCT probe substrate.
View Article and Find Full Text PDFThe effect of pregnancy-related hormones on hepatic transporters: studies with premenopausal human hepatocytes.
Front Pharmacol
August 2024
Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, United States.
Introduction: Pregnancy results in significant changes in drug pharmacokinetics (PK). While previous studies have elucidated the impact of pregnancy-related hormones (PRH) on mRNA or protein expression and activity of major hepatic metabolizing enzymes, their effect on hepatic drug transporters remains largely unexplored. Therefore, we investigated the effect of a cocktail of PRH on the mRNA expression and activity of hepatic transporters.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!